The court's decision substantially narrows the antitrust case against Teva, removing several high-risk theories. This reduces the litigation overhang on the stock. However, the DAW campaign and PBM agreement claims survive, so discovery will continue. Monitor for summary judgment motions and any settlement discussions. The ruling is a clear positive for Teva but does not eliminate the case entirely.
Price Chart
Executive Summary
The District Court of New Jersey adopted a Special Master's Report and Recommendation, partially granting Teva's motion to dismiss Mylan's antitrust lawsuit over Copaxone. The court dismissed with prejudice several key allegations, including claims related to citizen petitions, ANDA litigation, market shift, and copay assistance, while allowing the DAW campaign, exclusionary PBM agreements, and the 2020 reclassification petition/lawsuit to proceed. This significantly narrows the scope of the litigation and reduces Teva's potential antitrust exposure.
Court Ruling Details
Key Facts
- Court dismissed with prejudice allegations about 20mg citizen petitions, 20mg ANDA lawsuit, 2014 FDA lawsuit, 40mg ANDA lawsuit, non-Orange Book patent litigation, market shift, and copay assistance.
- Court struck foreign allegations from the complaint.
- Surviving claims: DAW campaign (false statements to doctors), exclusionary agreements with PBMs, and the 2020 reclassification petition/lawsuit.
- Lanham Act claim (Count II) and state law claims (Counts III-VI) also survive.
- No damages awarded; ruling is on motion to dismiss, not final judgment.
Financial Impact
The ruling eliminates several theories that could have resulted in significant damages if proven. The surviving claims are narrower, reducing the overall litigation risk. No specific dollar amount was awarded or stated in the opinion.
Risk Factors
- Surviving claims (DAW campaign, PBM agreements, 2020 reclassification) could still lead to liability after discovery.
- Mylan may appeal the dismissal of certain claims, though interlocutory appeal is unlikely.
- Discovery may reveal additional damaging facts that could expand the case.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2kgjc53a-TEVA |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.51 (+8.69%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.51 (+7.48%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.51 (+5.39%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.51 (+8.42%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.51 (+3.70%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.51 (+3.70%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.51 (+9.32%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.51 (+13.50%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.51 (+12.85%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.51 (+13.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access